Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. (Q45936276)

18 December 2017

title

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. (English)

1 reference

18 December 2017

1

P Ljungman

1 reference

18 December 2017

11

C Peters

1 reference

18 December 2017

Mats Brune

3

object named as

M Brune

1 reference

18 December 2017

author name string

M Bregni

2

1 reference

18 December 2017

J Cornelissen

4

1 reference

18 December 2017

T de Witte

5

1 reference

18 December 2017

G Dini

6

1 reference

18 December 2017

H Einsele

7

1 reference

18 December 2017

H B Gaspar

8

1 reference

18 December 2017

A Gratwohl

9

1 reference

18 December 2017

J Passweg

10

1 reference

18 December 2017

V Rocha

12

1 reference

18 December 2017

R Saccardi

13

1 reference

18 December 2017

H Schouten

14

1 reference

18 December 2017

A Sureda

15

1 reference

18 December 2017

A Tichelli

16

1 reference

18 December 2017

A Velardi

17

1 reference

18 December 2017

D Niederwieser

18

1 reference

18 December 2017

European Group for Blood and Marrow Transplantation

19

1 reference

18 December 2017

language of work or name

English

0 references

publication date

6 July 2009

1 reference

18 December 2017

Bone Marrow Transplantation

published in

1 reference

18 December 2017

volume

45

1 reference

18 December 2017

issue

2

1 reference

18 December 2017

page(s)

219-234

1 reference

18 December 2017

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Risk-adjusted outcome measurement in pediatric allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Megadose transplantation of highly purified haploidentical stem cells: current results and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle L

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

A comparison of allografting with autografting for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Autologous haematopoietic stem-cell transplantation in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Haploidentical stem cell transplantation for children with acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the F

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Double cord blood transplantation in patients with high risk bone marrow failure syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lympho

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Stem cell transplantation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Hematopoietic stem cell transplantation for systemic lupus erythematosus, the antiphospholipid syndrome and bullous skin diseases

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Autologous stem cell transplantation for systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Current perspectives of autologous stem cell transplantation for severe Juvenile Idiopathic Arthritis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2009.141

7 January 2021

Identifiers

DOI

10.1038/BMT.2009.141

1 reference

18 December 2017

Dimensions Publication ID

1046368259

0 references

1 reference

18 December 2017